Rob Stein
Rob Stein is a correspondent and senior editor on NPR's science desk.
An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.
Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.
Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.
Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.
Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.
-
The company said that when study participants were given a second jab after six months, their antibody levels were nine times higher than they were 28 days after a first dose of the COVID-19 vaccine.
-
Johnson & Johnson said that when it gave study participants a second jab after six months, their antibody levels were nine times higher than they were 28 days after a first dose of the COVID vaccine.
-
FDA gives full approval to Pfizer's COVID-19 vaccine, a highly anticipated move that could give the nation's vaccination campaign a badly needed boost.
-
The latest coronavirus surge is ratcheting up fears about the toll, and intensifying pressure to get more people vaccinated, wearing masks and perhaps start offering booster shots.
-
For the first time, scientists have shown that a new kind of genetic engineering can crash populations of malaria-spreading mosquitoes.
-
New estimates show the U.S. is on track to see a big rise in cases and more than triple the number of deaths by October.
-
With news about vaccinated people getting coronavirus infections, should you be worried? How common are breakthrough infections? Here's what scientists know and what they're trying to learn.
-
The highly contagious delta variant of the coronavirus is spreading fast and driving new cases and hospitalizations. Here's what you need to know to keep yourself and your kids from getting sick.
-
As the delta variant takes over in the U.S., new, localized outbreaks are emerging. Those surges are likely driven by pockets of dangerously low vaccination rates.
-
COVID-19 cases are increasing in many, poorly-vaccinated parts of the globe. We check in with reporters in Australia, Sierre Leone and with our science team to talk about the Delta variant's threats.